今晚新澳门9点35分开奖结果,49图库资料大全,澳门一肖中100%期期准海南特区号,2025澳门天天开好彩大全53期

深圳市第二人民醫(yī)院

　　深圳市第二人民醫(yī)院（深圳大學(xué)第一附屬醫(yī)院）始建于1980年，1996年創(chuàng)建為國(guó)家“三級(jí)甲等”醫(yī)院，是深圳市首批兩家“三甲”醫(yī)院之一。2008年經(jīng)教育部批準(zhǔn)，成為“深圳大學(xué)第一附屬醫(yī)院”。醫(yī)院先后獲得“全國(guó)衛(wèi)生先進(jìn)單位”、“全國(guó)五一勞動(dòng)獎(jiǎng)狀”、“深圳世界大學(xué)生運(yùn)動(dòng)會(huì)先進(jìn)集體”、“改善醫(yī)療服務(wù)示范醫(yī)院”等榮譽(yù)稱號(hào)。

　　2017年，牽頭成立深圳第一個(gè)“社康中心-區(qū)級(jí)醫(yī)院-市級(jí)醫(yī)院”分級(jí)診療和三級(jí)聯(lián)動(dòng)的緊密型醫(yī)聯(lián)體——深圳市大鵬新區(qū)醫(yī)療健康集團(tuán)；2018年，入選廣東省高水平醫(yī)院重點(diǎn)建設(shè)單位；2019年，以醫(yī)院為依托成立深圳市轉(zhuǎn)化醫(yī)學(xué)研究院，著力打造全市轉(zhuǎn)化醫(yī)學(xué)研究資源共享和服務(wù)平臺(tái)；2022年，在河套深港科技創(chuàng)新合作區(qū)成立深圳市第二人民醫(yī)院醫(yī)學(xué)創(chuàng)新技術(shù)轉(zhuǎn)化中心；同年，入選廣東省公立醫(yī)院改革與高質(zhì)量發(fā)展示范醫(yī)院；2023年，深圳大學(xué)第一臨床醫(yī)學(xué)院入選廣東省首批高水平臨床醫(yī)學(xué)院培育建設(shè)單位(全市唯一)，并獲批全市醫(yī)療衛(wèi)生系統(tǒng)首家具有博士后獨(dú)立招收資格的單位；2024年，深圳市第二人民醫(yī)院龍華醫(yī)院正式啟用，由深圳市第二人民醫(yī)院實(shí)行同質(zhì)化垂直管理，通過(guò)“一院多區(qū)”同品質(zhì)、一體化、數(shù)字化、特色化發(fā)展，推動(dòng)優(yōu)質(zhì)醫(yī)療資源下沉，打造以神經(jīng)系統(tǒng)疾病為特色的“強(qiáng)專科、大綜合”高水平醫(yī)院；2025年，入選廣東省中西醫(yī)協(xié)同“旗艦”醫(yī)院。2018年-2023年，連續(xù)六年在全國(guó)三級(jí)公立醫(yī)院績(jī)效考核中等級(jí)為A+，在全國(guó)參評(píng)的1588家三級(jí)綜合醫(yī)院中穩(wěn)居前10%。

深圳市第二人民醫(yī)院龍華醫(yī)院

　　學(xué)科建設(shè)

　　醫(yī)院以學(xué)科建設(shè)為抓手，努力打造“院有名科、科有特色、人有專長(zhǎng)”。持續(xù)強(qiáng)化學(xué)科內(nèi)涵建設(shè)，學(xué)科綜合實(shí)力顯著提升，結(jié)構(gòu)合理、優(yōu)勢(shì)突出的學(xué)科體系基本建成，形成了學(xué)科“腦強(qiáng)骨頭硬、燒傷五官?gòu)?qiáng)、重癥是保障”的鮮明特色。

　　截至目前，醫(yī)院共獲批國(guó)家、省、市臨床重點(diǎn)?？?2個(gè)，

　　其中國(guó)家臨床重點(diǎn)?？?個(gè)（骨科、神經(jīng)外科、燒傷科）；

　　國(guó)家中西醫(yī)協(xié)同“旗艦”科室建設(shè)項(xiàng)目1個(gè)（中西醫(yī)結(jié)合科）

　　廣東省高水平臨床重點(diǎn)?？?個(gè)（骨科、神經(jīng)外科、耳鼻咽喉科、燒傷科、重癥醫(yī)學(xué)科、口腔科）；

　　廣東省臨床重點(diǎn)?？?個(gè)（運(yùn)動(dòng)醫(yī)學(xué)科、泌尿外科、神經(jīng)內(nèi)科、腎病科、血液內(nèi)科）；

　　廣東省中醫(yī)重點(diǎn)專科2個(gè)（中西醫(yī)結(jié)合腫瘤科、中西醫(yī)結(jié)合老年病科）;

　　深圳市臨床重點(diǎn)?？?專病11個(gè)（脊柱外科、運(yùn)動(dòng)醫(yī)學(xué)科、手外科、泌尿外科、血液內(nèi)科、康復(fù)醫(yī)學(xué)科、腎病科、介入科、護(hù)理、臨床藥學(xué)科、腦卒中）；

　　深圳市中醫(yī)特色專科3個(gè)（老年病科、針灸推拿科、腫瘤科）；

　　深圳市非中醫(yī)類醫(yī)院中西醫(yī)協(xié)同“旗艦”科室1個(gè)（中醫(yī)科）；

　　國(guó)家級(jí)臨床醫(yī)學(xué)研究中心分中心（網(wǎng)絡(luò)成員）共5個(gè)：國(guó)家骨科與運(yùn)動(dòng)康復(fù)臨床醫(yī)學(xué)研究中心核心單位、國(guó)家血液系統(tǒng)疾病臨床醫(yī)學(xué)研究中心分中心、國(guó)家代謝病疾病臨床醫(yī)學(xué)研究中心深圳分中心、國(guó)家耳鼻咽喉疾病臨床醫(yī)學(xué)研究中心網(wǎng)絡(luò)成員單位及大灣區(qū)分中心、國(guó)家神經(jīng)系統(tǒng)疾病臨床醫(yī)學(xué)研究中心區(qū)域分中心；

　　國(guó)家藥物臨床試驗(yàn)機(jī)構(gòu)（GCP）共28個(gè):血液內(nèi)科、內(nèi)分泌科、腎病學(xué)專業(yè)、呼吸內(nèi)科、骨科、燒傷科、神經(jīng)外科、泌尿外科、甲乳外科、肝膽外科、胸外科、中西醫(yī)結(jié)合科、重癥醫(yī)學(xué)部、耳鼻咽喉科、神經(jīng)內(nèi)科、婦科、皮膚科、急診科、口腔科、肛腸外科、腫瘤科、風(fēng)濕免疫科、麻醉科、中醫(yī)老年、消化內(nèi)科、康復(fù)科、Ⅰ期臨床試驗(yàn)研究室-生物等效性試驗(yàn)、Ⅰ期臨床試驗(yàn)研究室-I期藥物臨床試驗(yàn)；

　　國(guó)家級(jí)住院醫(yī)師規(guī)范化培訓(xùn)基地共25個(gè)：內(nèi)科、兒科、急診科、神經(jīng)內(nèi)科、全科、康復(fù)醫(yī)學(xué)科、外科、外科（神經(jīng)外科方向）、外科（胸心外科方向）、外科（泌尿外科方向）、外科（整形外科方向）、骨科、婦產(chǎn)科、眼科、耳鼻咽喉科、麻醉科、臨床病理科、檢驗(yàn)醫(yī)學(xué)科、放射科、超聲醫(yī)學(xué)科、口腔全科、皮膚科、核醫(yī)學(xué)科、口腔頜面外科、重癥醫(yī)學(xué)科；

　　國(guó)家級(jí)重點(diǎn)實(shí)驗(yàn)室4個(gè)：腫瘤基因組臨床應(yīng)用關(guān)鍵技術(shù)國(guó)家地方聯(lián)合工程實(shí)驗(yàn)室、國(guó)家地方聯(lián)合醫(yī)學(xué)合成生物學(xué)工程實(shí)驗(yàn)室(深圳大學(xué)共建) 、國(guó)家中醫(yī)藥管理局蛋白組學(xué)實(shí)驗(yàn)室（三級(jí)）、國(guó)家中醫(yī)藥管理局舌診原理與應(yīng)用重點(diǎn)研究室；

　　廣東省創(chuàng)新平臺(tái)、實(shí)驗(yàn)室共6個(gè)：廣東省智能化數(shù)字骨科工程技術(shù)研究中心、廣東省腦血管病轉(zhuǎn)化醫(yī)學(xué)創(chuàng)新平臺(tái)、廣東省人工智能生物醫(yī)學(xué)創(chuàng)新平臺(tái)、廣東省運(yùn)動(dòng)醫(yī)學(xué)工程技術(shù)研究中心、廣東省泌尿生殖腫瘤系統(tǒng)與合成生物學(xué)重點(diǎn)實(shí)驗(yàn)室，廣東省腫瘤基因組臨床應(yīng)用工程技術(shù)研究中心；

　　深圳市重點(diǎn)實(shí)驗(yàn)室、工程實(shí)驗(yàn)室共12個(gè)：深圳市組織工程重點(diǎn)實(shí)驗(yàn)室、蛋白質(zhì)組學(xué)中醫(yī)藥三級(jí)實(shí)驗(yàn)室、舌診原理與應(yīng)用重點(diǎn)研究室、分子醫(yī)學(xué)診斷重點(diǎn)實(shí)驗(yàn)室、深圳市泌尿生殖系統(tǒng)腫瘤研究重點(diǎn)實(shí)驗(yàn)室、深圳細(xì)胞生物技術(shù)轉(zhuǎn)化醫(yī)學(xué)重點(diǎn)實(shí)驗(yàn)室、深圳腦損傷與修復(fù)轉(zhuǎn)化醫(yī)學(xué)重點(diǎn)實(shí)驗(yàn)室、深圳市醫(yī)學(xué)重編程技術(shù)重點(diǎn)實(shí)驗(yàn)室、深圳市生物材料轉(zhuǎn)化醫(yī)學(xué)重點(diǎn)實(shí)驗(yàn)室、深圳市醫(yī)學(xué)檢驗(yàn)分子診斷重點(diǎn)實(shí)驗(yàn)室、免疫基因治療工程實(shí)驗(yàn)室（提升）、深圳市微生物基因組修飾編輯與應(yīng)用重點(diǎn)實(shí)驗(yàn)室；

　　深圳市公共平臺(tái)共10個(gè)：深圳市馴化器官工程技術(shù)研究開(kāi)發(fā)中心、深圳市腦損傷與修復(fù)工程技術(shù)研究開(kāi)發(fā)中心、深圳市運(yùn)動(dòng)醫(yī)學(xué)工程技術(shù)研究開(kāi)發(fā)中心、深圳市重大疾病體外診斷公共技術(shù)服務(wù)平臺(tái)、深圳市腦卒中篩查與防治公共技術(shù)服務(wù)平臺(tái)、深圳市藥物臨床試驗(yàn)公共技術(shù)服務(wù)平臺(tái)、深圳骨髓移植技術(shù)臨床應(yīng)用公共服務(wù)平臺(tái)、深圳市眩暈診治與前庭功能重塑公共技術(shù)服務(wù)平臺(tái)、深圳市中小學(xué)生脊柱側(cè)彎篩查服務(wù)平臺(tái)、深圳市青少年脊柱健康智能診療與防控公共服務(wù)平臺(tái)；

　　深圳市研究所共7個(gè)：深圳市血液病研究所、深圳市老年醫(yī)學(xué)研究所、深圳市中西醫(yī)結(jié)合研究所、深圳大學(xué)泌尿生殖研究所、深圳大學(xué)糖尿病研究所、深圳大學(xué)呼吸疾病研究所、深圳市燒傷整形與創(chuàng)面修復(fù)研究所；

　　深圳市醫(yī)療質(zhì)量控制中心共9個(gè)：臨床用血質(zhì)量控制中心、消毒供應(yīng)質(zhì)量控制中心、神經(jīng)系統(tǒng)疾病質(zhì)量控制中心、泌尿外科臨床質(zhì)量控制中心、康復(fù)醫(yī)療質(zhì)量控制中心、耳鼻咽喉科專業(yè)質(zhì)量控制中心、介入治療質(zhì)量控制中心、日間醫(yī)療管理質(zhì)量控制中心、互聯(lián)網(wǎng)醫(yī)療管理質(zhì)量控制中心；

　　引進(jìn)“孔雀計(jì)劃”團(tuán)隊(duì)共3個(gè)：腫瘤生物標(biāo)準(zhǔn)物與免疫細(xì)胞治療團(tuán)隊(duì)、組織修復(fù)與再生的關(guān)鍵科技和醫(yī)療新技術(shù)研究創(chuàng)新團(tuán)隊(duì)、常見(jiàn)惡性腫瘤的精準(zhǔn)醫(yī)學(xué)研發(fā)團(tuán)隊(duì)；

　　引進(jìn)“三名工程”團(tuán)隊(duì)43個(gè)：首都醫(yī)科大學(xué)附屬北京天壇醫(yī)院王擁軍教授神經(jīng)學(xué)科團(tuán)隊(duì)；北京大學(xué)第三醫(yī)院敖英芳教授運(yùn)動(dòng)醫(yī)學(xué)專家團(tuán)隊(duì)；北京積水潭醫(yī)院王滿宜創(chuàng)傷骨科治療團(tuán)隊(duì)；中國(guó)科學(xué)院上海營(yíng)養(yǎng)與健康研究所趙國(guó)屏院士腫瘤精準(zhǔn)治療團(tuán)隊(duì)；南京醫(yī)科大學(xué)戴一凡教授馴化器官團(tuán)隊(duì)；加拿大麥吉爾大學(xué)及蒙特利爾神經(jīng)疾病研究所團(tuán)隊(duì)；廣州復(fù)大腫瘤醫(yī)院徐克成團(tuán)隊(duì)；南方醫(yī)科大學(xué)南方醫(yī)院侯凡凡院士腎內(nèi)科團(tuán)隊(duì)；南京醫(yī)科大學(xué)附屬第一醫(yī)院勵(lì)建安院士康復(fù)醫(yī)學(xué)團(tuán)隊(duì)；深圳華大生命科學(xué)研究院楊煥明院士產(chǎn)科團(tuán)隊(duì)；北醫(yī)三院劉忠軍教授脊柱骨科團(tuán)隊(duì)；中山大學(xué)附屬第一醫(yī)院成守珍教授專科護(hù)理團(tuán)隊(duì)；上海長(zhǎng)海醫(yī)院血管外科景在平教授創(chuàng)新團(tuán)隊(duì)；北京大學(xué)人民醫(yī)院郭衛(wèi)教授骨腫瘤團(tuán)隊(duì)；復(fù)旦大學(xué)附屬眼耳鼻喉科醫(yī)院李華偉教授耳鼻喉科團(tuán)隊(duì)；復(fù)旦大學(xué)附屬醫(yī)院邵志敏教授乳腺外科團(tuán)隊(duì)；中國(guó)醫(yī)學(xué)科學(xué)院血液病醫(yī)院王建祥教授血液內(nèi)科團(tuán)隊(duì)；西南醫(yī)院吳軍教授燒傷外科團(tuán)隊(duì)；上海交通大學(xué)口腔醫(yī)學(xué)院口腔科邱蔚六院士團(tuán)隊(duì)；中國(guó)醫(yī)學(xué)科學(xué)院阜外醫(yī)院高潤(rùn)霖院士團(tuán)隊(duì)；北京大學(xué)第一醫(yī)院郭應(yīng)祿院士/周利群教授泌尿外科團(tuán)隊(duì)；北京協(xié)和醫(yī)院金征宇教授放射影像診斷團(tuán)隊(duì)；北京協(xié)和醫(yī)院劉曉紅老年醫(yī)學(xué)團(tuán)隊(duì)；中南大學(xué)湘雅二醫(yī)院周智廣教授代謝內(nèi)分泌團(tuán)隊(duì)；中國(guó)人民解放軍總醫(yī)院第四醫(yī)學(xué)中心姚詠明教授重癥醫(yī)學(xué)科團(tuán)隊(duì)；上海交通大學(xué)醫(yī)學(xué)院附屬瑞金醫(yī)院麻醉科于布為教授團(tuán)隊(duì)；首都醫(yī)科大學(xué)附屬北京安貞醫(yī)院劉迎龍教授先天性心臟病產(chǎn)前-產(chǎn)后一體化管理團(tuán)隊(duì)；中國(guó)科學(xué)院生物物理研究所閻錫蘊(yùn)院士納米酶應(yīng)用轉(zhuǎn)化團(tuán)隊(duì)；中國(guó)中醫(yī)科學(xué)院西苑醫(yī)院陳可冀院士中西醫(yī)結(jié)合老年醫(yī)學(xué)團(tuán)隊(duì)；西南醫(yī)院（第三軍醫(yī)大學(xué)第一附屬醫(yī)院）唐康來(lái)教授足踝外科團(tuán)隊(duì)；南京醫(yī)科大學(xué)第一附屬醫(yī)院王學(xué)浩院士肝臟外科團(tuán)隊(duì)；華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬同濟(jì)醫(yī)院馬丁院士婦科惡性腫瘤精準(zhǔn)診斷與治療團(tuán)隊(duì)；江南大學(xué)附屬醫(yī)院呂國(guó)忠教授燒傷整形外科團(tuán)隊(duì)；北京積水潭醫(yī)院田文教授手外科團(tuán)隊(duì)；上海交通大學(xué)醫(yī)學(xué)院附屬瑞金醫(yī)院陳德昌教授重癥醫(yī)學(xué)團(tuán)隊(duì)；中國(guó)人民解放軍總醫(yī)院朱平教授老年醫(yī)學(xué)科團(tuán)隊(duì)；成都中醫(yī)藥大學(xué)梁繁榮教授針灸學(xué)經(jīng)穴效應(yīng)臨床研究團(tuán)隊(duì)；西澳大學(xué)馬歇爾教授幽門螺旋桿菌研究團(tuán)隊(duì)；哈佛醫(yī)學(xué)院附屬斯波爾丁康復(fù)醫(yī)院海曼院士醫(yī)養(yǎng)康復(fù)團(tuán)隊(duì)；復(fù)旦大學(xué)附屬兒科醫(yī)院王藝教授兒童神經(jīng)專業(yè)團(tuán)隊(duì)； 成都中醫(yī)藥大學(xué)梁繁榮教授針灸學(xué)經(jīng)穴效應(yīng)臨床研究團(tuán)隊(duì)；河北醫(yī)科大學(xué)叢斌院士病理診斷團(tuán)隊(duì)；上海交通大學(xué)附屬仁濟(jì)醫(yī)院呂良敬教授自身免疫病診治團(tuán)隊(duì)。

深圳市轉(zhuǎn)化醫(yī)學(xué)研究院

　　科研成果

　　近五年來(lái)，醫(yī)院作為首席科學(xué)家單位牽頭科技部重點(diǎn)研發(fā)計(jì)劃4項(xiàng)，承擔(dān)（子）課題8項(xiàng)；主持國(guó)家自然科學(xué)基金項(xiàng)目160項(xiàng)，其中承擔(dān)重大項(xiàng)目1項(xiàng)、重點(diǎn)國(guó)際合作項(xiàng)目2項(xiàng)；獲批省市級(jí)科技計(jì)劃600余項(xiàng)；各級(jí)科研經(jīng)費(fèi)累計(jì)達(dá)5億元。醫(yī)院榮獲國(guó)家、省市級(jí)科技獎(jiǎng)33項(xiàng)；發(fā)表SCI論文1950篇，最高影響因子達(dá)72.087，JCR二區(qū)及以上占比達(dá)76%；授權(quán)國(guó)家專利1361項(xiàng)，其中發(fā)明專利226項(xiàng)。在Nature出版集團(tuán)發(fā)布的自然指數(shù)排行榜中，醫(yī)院2016-2021年連續(xù)六年進(jìn)入全國(guó)醫(yī)療機(jī)構(gòu)前百?gòu)?qiáng)；科睿唯安（原湯森路透）公布的ESI排名，醫(yī)院臨床醫(yī)學(xué)學(xué)科于2019-2023年連續(xù)五年躋身ESI世界前1%；2023年度中國(guó)醫(yī)院科技量值（STEM），15個(gè)學(xué)科進(jìn)入2023年度中國(guó)醫(yī)院科技量值全國(guó)百?gòu)?qiáng)，15個(gè)學(xué)科進(jìn)入2019-2023五年醫(yī)院總科技量值全國(guó)百?gòu)?qiáng)；首兩屆中國(guó)醫(yī)院創(chuàng)新轉(zhuǎn)化排行榜發(fā)布，深圳市第二人民醫(yī)院排名保持在全國(guó)前24位。醫(yī)院堅(jiān)持以“高質(zhì)量創(chuàng)新發(fā)展”為導(dǎo)向、以臨床需求為引導(dǎo)，鼓勵(lì)學(xué)科交叉合作，不斷推進(jìn)成果轉(zhuǎn)化，完成醫(yī)學(xué)成果轉(zhuǎn)化24項(xiàng)，直接受益達(dá)650萬(wàn)元，為助力高水平研究型醫(yī)院建設(shè)持續(xù)發(fā)力！　　

　　教學(xué)情況

　　醫(yī)院作為深圳大學(xué)第一附屬醫(yī)院和第一臨床醫(yī)學(xué)院，是深圳市首批獲批的三家住培基地之一臨床教學(xué)與醫(yī)療實(shí)踐緊密結(jié)合，建立了深圳市衛(wèi)生系統(tǒng)中完整的教學(xué)體系；始終堅(jiān)持“醫(yī)教協(xié)同”的發(fā)展理念，積極整合院內(nèi)外優(yōu)質(zhì)教育資源，教學(xué)水平得到了全面提升。醫(yī)院現(xiàn)有博士研究生培養(yǎng)專業(yè)4個(gè),博士研究生指導(dǎo)教師22名；碩士研究生培養(yǎng)專業(yè)25個(gè),碩士研究生指導(dǎo)教師173名，臨床帶教師資635名；2007年獲“博士后創(chuàng)新實(shí)踐基地”稱號(hào)，2013年獲批深圳市醫(yī)院“博士后科研工作站”。2023年深圳大學(xué)第一臨床醫(yī)學(xué)院成功入選廣東省首批高水平臨床醫(yī)學(xué)院培育建設(shè)單位，是深圳市唯一入選的單位。我院是國(guó)家首批住院醫(yī)師規(guī)范化培訓(xùn)基地（基地編號(hào)：44126），目前擁有住培專業(yè)基地25個(gè)，其中康復(fù)醫(yī)學(xué)科為省級(jí)住培重點(diǎn)專業(yè)基地。三家協(xié)同單位：深圳市婦幼保健院、寶安區(qū)中心醫(yī)院、深圳市中西醫(yī)結(jié)合醫(yī)院。

　　奮進(jìn)新時(shí)代，邁進(jìn)新征程。醫(yī)院始終以人民健康為中心，搶抓“雙區(qū)驅(qū)動(dòng)”“雙區(qū)疊加”重大機(jī)遇，以學(xué)科建設(shè)和科技創(chuàng)新為引擎，以黨建為引領(lǐng)，以國(guó)家區(qū)域醫(yī)療中心、國(guó)家臨床重點(diǎn)?？?、國(guó)家醫(yī)學(xué)研究中心建設(shè)為抓手，形成“一院多區(qū)、一體多翼、協(xié)同發(fā)展”新格局，致力打造醫(yī)療技術(shù)頂尖、醫(yī)療質(zhì)量過(guò)硬、醫(yī)療服務(wù)高效、醫(yī)院管理精細(xì)的粵港澳大灣區(qū)學(xué)科特色鮮明的高水平研究型醫(yī)院及區(qū)域性醫(yī)療中心。

Shenzhen Second People's Hospital

　　Shenzhen Second People's Hospital was established in 1980, is a modern comprehensive hospital integrating medical treatment, teaching, scientific research, rehabilitation, preventive healthcare, and health education. In 2008, with approval from the Ministry of Education, the hospital became the “First Affiliated Hospital of Shenzhen University”.

　　The hospital occupies a land area of 37,000 m2 with a built area of 136,000 m2 and operates with 1,910 open beds.

　　The hospital has 3,369 employees, 1,034 doctors and 1,343 nurses. Among them, there are 746 with senior titles, 386 with doctorate degrees, 7 experts enjoying the State Council's special governmental allowance, and 98 post-doctoral fellows in residence.

　　In 2023, Our annual outpatient and emergency visits exceeded 2.06 million, and the number of discharged patients reached 91,438. 

　　As a key construction unit of high-level hospitals in Guangdong Province, among the ranks of advanced general hospitals in South China, which is the public hospital trusted by the people. We have always been adhering to the hospital motto: dedication, love, unity and dedication for creating a modern first-class brand hospital.

　　Top ranking for the performance evaluation in public hospitals.

　　From 2018 to 2022, the hospital has consistently achieved A+ for five consecutive years in the national performance assessment of 3A-grade public hospitals, and we have been steadily ranked among the top 100 in China with the best result being No.52 .

　　From 2018 to 2021, we ranked in the top 10 in the "Provincial Examination" for four consecutive years in Guangdong Province, of which the best score was No.3.

　　From 2018 to 2021, we ranked in the top 2 in the "City Examination" results for four consecutive years, of which were ranked No.1 in 2020.

　　Currently, we have 30 National, Provincial and Municipal key medical disciplines.

　　The hospital focuses on developing distinctive , strong disciplines, resulting in a profile of ‘strong brain and bones, excellence in burns and five senses, and guaranteed serious illness’.

　　3 National Key Clinical Medical Specialties: Orthopedics, Neurosurgery, Burn Medicine.

　　6 Guangdong High-Level Clinical Key Specialties: Orthopedics, Neurosurgery, Otorhinolaryngology, Intensive Care Medicine, Burn Medicine, and Stomatology.

　　5 Guangdong Provincial Clinical Key Specialties: Urology, Sports Medicine, Neurology, Nephrology, and Hematology.

　　We continue to develop a series of new technologies and programs to build a high-level hospital.

　　We have new technologies and advanced equipments, including luminal, robotic surgery, PET-CT, spiral CT, DSA, Da Vinci robot, strive to create a technology-driven clinical discipline group, and carry out robotic surgery and other international cutting-edge high-precision treatment technologies. In the past five years, we have carried out more than 130 pioneering new technologies and projects at home and abroad, and led or participated in the formulation of more than 110 diagnostic and treatment standards, guidelines, consensus and technical specifications.

　　The Foot and Ankle Surgery team completed the international first case of minimally invasive treatment for talus cartilage injury with reverse drilling under robotic navigation.

　　The Functional Neurology Department, in cooperation with Corning Hospital and Tsinghua University, completed the international first case of ROSA robot-assisted 3T MRI-compatible DBS stimulation of the lateral rein nucleus for treatment of refractory depression, epoch-making Shenzhen as a city capable of conducting psychosurgery.

　　The Burns and Plastic Surgery Department successfully treated a 12-year-old child with 97% TBSA third-degree burns, reaching the world's leading standards and reflecting the hospital's comprehensive treatment level and ability to treat public emergencies.

　　We strive to promote Innovation and Research Breakthroughs， upgrade the core competence of medical discipline.  

　　Our unwavering drive to build a high-level scientific research platform to enhance medical innovation and transformation capabilities.

　　In 2019, relying on our hospital, the Shenzhen Institute of Translational Medicine (SITM) was established, dedicated to creating a shared service platform for translational medicine research resources across Shenzhen.

　　In 2022, the Shenzhen Second People's Hospital Medical Innovation Technology Transfer Center was established in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.

　　We have 4 national scientific research platforms, 5 national clinical medical research center sub-centers (member units), and 42 provincial and municipal laboratories and platforms.

　　Frome 2016 to 2022, we consistently ranked among tht top 100 nationalo medical constitutions in the Nature Index rankings published by the Nature Publishing Group. In the ESI ranking, our 's clinical medicine discipline has been in the top 1% worldwide for five consecutive years (2019 to 2023), with 14 disciplines have consistently ranked within the top 100 nationally in total scientific and technological value (ASTEM) for five consecutive years.

　　In the second "Chinese Hospital Innovation and Transformation Ranking List", we ranked 24^th nationwide and No.1 in Shenzhen.

　　We actively carry out international exchanges and cooperation, and have introduced a number of medical experts at home and abroad.

　　Our international exchanges and cooperation began in 1986. Since December 2014, in order to comprehensively improve the quality of healthcare in Shenzhen, and build an international medical center, the Shenzhen Municipal Government has been carrying out the "Sanming Project of Healthcare". The project aims to cultivate famous doctors, hospitals and clinics in Shenzhen, attract first-class medical talents and teams from home and abroad, build high-level hospitals, and improve the overall level of medical technology in Shenzhen, so as to satisfy the growing needs of the public for healthcare.

　　We have introduced 3 foreign "Peacock Plan" teams and 35 "Sanming Project" teams, the number of which is the highest in Shenzhen, including Professor. Guy Rouleau's team from the Montreal Neurological Institute of McGill University in Canada, Professor. Marshall's team from the University of Western Australia in Australia, Professor Guy Rouleau of Montreal Neurological Institute of McGill University, Professor Marshall of University of Western Australia, and Academician Hyman of Spalding Rehabilitation Hospital of Harvard Medical School are among the top teams from overseas hospitals.

　　The team includes 1 Nobel Prize laureate, 11 academicians, and 23 national first-class clinical experts.

　　We focus on major diseases, and have strengthened the capacity building for accurate prevention and treatment of major diseases.

　　We have been approved as the provincial center of the National Diabetes Standardized Prevention and Control Center and holds 3 Shenzhen Major Disease Prevention and Control Centers, which owns the largest number of such centers in Shenzhen.

　　We have actively promoted the medical and preventive integration program for neurological diseases and metabolic diseases in Shenzhen, and provided screening, prevention, treatment and care services in the whole process.

　　We took the lead in establishing the "Shenzhen Youth Spine Health Center", conducting scoliosis screenings in over 1,000 primary and secondary schools, with more than 5 million screenings completed to date.

　　Our "Thrombolysis Map" continues to play an exemplary role in the country, radiating to nearly 130 hospitals nationwide.   

　　We have always carried out foreign-aid medical work.

　　Since 1995, we have repeatedly sent professional and technical personnel to participate in foreign aid medical missions, treating common and frequent diseases in African countries and performing surgeries like cardiac and tumor remocal, which have saved a large number of lives.

　　We are the first completed teaching system within Shenzhen health system.

　　As the First Affiliated Hospital and the first clinical medical college of Shenzhen University, we closely integrate clinical teaching with medical practice and have established the first comprehensive teaching system within Shenzhen health sector. It currently has 25 national resident standardized training bases.

　　We are the first hospital in Shenzhen to be approved as the post-doctoral research station.

　　In July 2023, the hospital was officially approved for independent recruitment qualification for postdoctoral research stations, becoming the first hospital in Shenzhen to be approved as the postdoctoral research station. This platform facilitates the introduction of 26 young high-level doctoral talents.